Urea is transported by urea transporter proteins in kidney, erythrocytes, and other tissues. Mice in which different urea transporters have been knocked out have urine-concentrating defects, which has led to the development and testing of urea transporters Slc14A2 (UT-A) and Slc14A1 (UT-B) inhibitors as urearetics. This review summarizes the knowledge gained during the past year on urea transporter regulation and investigations into the clinical potential of urearetics.
INTRODUCTION
Urea is a small, highly polar molecule with low lipid solubility across artificial lipid bilayers [1] . Although urea's permeability across artificial lipid bilayers is quite low, it is not zero. A specific facilitated urea transport process was first proposed in kidney in 1987 [2] . Subsequent physiologic studies led to the characterization of two families of urea transporters: Slc14A2 (UT-A) and Slc14A1 (UT-B) [3, 4] .
UT-A1 is the largest UT-A protein and is expressed in the apical plasma membrane in the inner medullary collecting duct (IMCD) (Fig. 1) . UT-A3 is also expressed in the IMCD, predominantly in the basolateral plasma membrane. UT-A2 is expressed in the thin descending limb [3, 4] . UT-B1 is expressed in the descending vasa recta and several extra-renal tissues. In humans, UT-B1 protein is the Kidd antigen. UT-B2 mRNA is expressed in cow and sheep rumen [3, 4] .
Urea transporters play an important role in the kidney under both normal and pathophysiological situations [3, 4] . Several knockout mice lacking urea transporters, such as UT-A1 and UT-A3 [5] [6] [7] , UT-A2 [8] , UT-B1 [9] [10] [11] , or UT-A2 and UT-B1 [12] , have been generated and have decreased maximal urineconcentrating ability, demonstrating that urea transporters play a major role in urinary concentration. They also raise the possibility that inhibition of urea transporters may be a target for the development of novel diuretics (urearetics).
In the past year, significant progress has been made in understanding the posttranslational modifications that regulate UT-A1 in the IMCD and in the development and testing of UT-A and UT-B inhibitors as urearetics. This review summarizes the knowledge gained during the past year on urea transporter regulation and on the clinical potential of urearetics.
UREA TRANSPORTER: SLC14A2
Protein kinase A UT-A1 contains several consensus sites for phosphorylation [3, 4] (Fig. 2) . Previous studies showed that S486 and S499 were protein kinase A (PKA) phosphorylation sites [13, 14] . A polyclonal antibody was used to localize phospho-S486-UT-A1 to the apical plasma membrane in vasopressin-treated rat IMCD [15] .
These findings were recently extended by the generation of a polyclonal antibody to phospho-S499-UT-A1, which also permitted investigation into the relationship of these two PKA-sensitive sites [16 & ]. Similarly to phospho-S486-UT-A1, phospho-S499-UT-A1 was primarily located to the apical plasma membrane; however, the two PKA phosphorylations were independent from one another [16 & ]. Finally, this study showed that activation of the exchange protein activated by cyclic AMP pathway, increases UT-A1 phosphorylation but not at either S486 or S499 [16 & ]. Satavaptan, a selective inhibitor of the type 2 vasopressin receptor (V2R), was used in a phosphoproteomic study to determine a system-wide analysis of the effect of vaptans [17] . Satavaptan
KEY POINTS
PKA not only activates UT-A1 but also promotes UT-A1 degradation through 14-3-3g, providing a feedback mechanism to return UT-A1 function to its basal state following stimulation by vasopressin.
PKC may promote sialyation of UT-A1 and inhibition of PKC may be important for ameliorating the osmotic diuresis caused by glucosuria in patients with diabetes mellitus.
Human kidney UT-B is localized to descending vasa recta, with expression decreasing with depth below the outer medulla, and also to the papillary surface epithelium, providing a paracellular pathway for urea transport across this epithelium.
As UT-A1 is located in the last portion of the IMCD, urearetics that target UT-A1 may have less risk for sideeffects, such as hypokalemia, than conventional diuretics. Diagram of transporters involved in urine concentration. In the center is a diagram of the nephron with CTX, OM and IM marked. Oval enlargements show locations of the NKCC2 and the ROMK channel in the thick ascending limb, AQP2-4 in the IMCD and UT-A1 and UT-A3 in the IMCD. Top left enlargement shows IMCD cells with UT-A1 located apically and UT-A3 located basolaterally. AQP2-4, aquaporins 2-4; CTX, cortex; IM, inner medulla; IMCD, inner medullary collecting duct; NKCC2, sodium potassium 2 chloride cotransporter; OM, outer medulla; ROMK, renal outer medullary potassium; UT-A, urea transporter Slc14A2.
blocked V2R-mediated activation of basophilic kinases and V2R-mediated inhibition of prolinedirected kinases [17] . Thus, satavaptan affected many of the same signaling pathways that are affected by vasopressin [17] . The 14-3-3 proteins regulate protein function by binding to phosphorylated serine or threonine residues. 14-3-3g was shown to bind to UT-A1, and activation of PKA enhanced this binding [18 && ]. 14-3-3g decreased urea transport and increased UT-A1 ubiquitination and degradation by interacting with the E3 ubiquitin ligase, mouse double minute 2 homolog [18 && ]. Thus, PKA activation increases UT-A1 phosphorylation, and the subsequent binding of 14-3-3g leads to UT-A1 degradation. If these two opposing effects are separated temporally, they could provide a negative feedback mechanism to return UT-A1 function to its basal state following stimulation by vasopressin [18 && ] (Fig. 3 ). The data showing these opposite effects of PKA are established, but whether there is a negative feedback loop, or whether only one effect is dominant in vivo, remains to be determined.
Both UT-A1 and UT-A3 are expressed in the IMCD [3, 4] . To determine the effect of UT-A1 alone, a mouse expressing only UT-A1 was created by transgenic restoration of UT-A1 into a UT-A1/UT-A3 knockout mouse [19 & ]. These UT-A1-only mice had normal basal urea permeability in the IMCD, but, unlike wild-type mice, vasopressin did not stimulate urea permeability [19 & ]. Urine concentrating ability, absent in UT-A1/UT-A3 knockout mice, was restored in the UT-A1 only mice [19 & ].
Protein kinase C
UT-A1 is also phosphorylated by protein kinase C (PKC) [20] [21] [22] . A recent study used mutagenesis to identify S494 as the PKC phosphorylation site [23 & ] (Fig. 2) . A polyclonal antibody to phospho-S494-UT-A1 was generated and used to show that activators of PKC, phorbol dibutyrate and hypertonicity, increased UT-A1 phosphorylation at S494 whereas activators of either PKA or exchange protein activated by cyclic AMP did not [23 & ]. Activation of both PKA and PKC, but not PKC alone, increased the apical plasma membrane accumulation of that UT-A1 [23 & ]. These findings suggest that UT-A1 phosphorylation at S494 by PKC may increase vasopressin-stimulated urea transport by enhancing UT-A1 retention in the apical plasma membrane [23 & ]. PKCa knockout mice have a urine concentrating defect [20] . Interestingly, PKCa knockout mice are protected against lithium-induced nephrogenic diabetes insipidus [24] . Compared with wild-type mice, lithium-treated PKCa knockout mice had no polyuria after 5 days of lithium and significantly less polyuria after 6 weeks, and UT-A1 protein abundance was unchanged at either time point [24] . Thus, knockout of PKCa prevented the 
Other recent findings
Urea permeability was measured in inner medullary thin limb segments from Munich-Wistar rats [31] . Urea permeability was lower in the upper portion of the thin descending limb than in the lower portion or the thin ascending limb. The urea permeability in the upper portion of the thin descending limb was not inhibited by phloretin, suggesting that it is not mediated by UT-A2 [31] . A recent molecular cloning study identified two novel variants of UT-A2, named UT-A2c and UT-A2d, as well as a variant of the sodium-glucose transporter 1 named SGLT1a, that may mediate the high urea permeability in the lower portion of the thin descending limb and the thin ascending limb segments [32 & ]. Two nonsteroidal anti-inflammatory drugs, meloxicam and ibuprofen, alter the phosphorylated forms of aquaporin-2 [33] . However, neither medication altered total UT-A1 phosphorylation in rat inner medulla [33] .
Succinylated gelatin was used to create a rat model of hepatorenal syndrome or abdominal compartment syndrome [34] . UT-A2 and UT-A3 mRNA abundances were reduced in the renal medulla of rats with hepatorenal syndrome compared with those with cirrhosis [34] . There was no difference in UT-A2, UT-A3, or UT-B mRNA abundances between rats with abdominal compartment syndrome and control rats [34] . There was no change in UT-A1 protein abundance in any of the groups of rats [34] .
Lipopolysaccharides were used to create a mouse model of endotoxemia and UT-A3 was measured in brain [35] . There was a significant decrease in UT-A3 protein abundance in the hippocampus and cortical Urea transporters and urearetics Klein and Sands astrocytes, and this decrease was partially restored by treatment with dexamethasone [35] . A recent review analyzed the evolution of urea transporters in vertebrates [36] . This analysis showed that three homologues, UT-A, UT-C, and UT-D, evolved from a single ancestral urea transporter in piscine lineages, followed by a reduction to a single UT-A [36] . An internal tandem duplication led to UT-A1, and a second duplication led to UT-B [36] . They propose that nonornithine-urea cycle production of urea is important for the generation of polyamines and neurotransmitters, and provided an evolutionary driving force for urea transporter expression in extra-renal tissues [36] . Another recent review suggests that urea transporters in skin may be involved in the development of uremic frost as both UT-A1 and UT-B are expressed in skin [37] .
UREA TRANSPORTERS: SLC14A1
Vasa recta UT-B is expressed in erythrocytes and descending vasa recta [3, 4] . Rat outer medullary descending vasa recta have been successfully studied by perfusion [38] . Recently, a technique was developed to perfuse rat inner medullary descending vasa recta [39 & ]. These inner medullary descending vasa recta also express UT-B [39 & ]. UT-B inhibition plays an important role in regulating blood pressure and vaso-relaxation via upregulation of the L-arginine-eNOS-NO pathway [40 && ]. In human kidney, UT-B protein expression was found in descending vasa recta, with expression decreasing with depth below the outer medulla [41 && ]. UT-B protein expression was also found in the papillary surface epithelium in the lower inner medulla, providing a paracellular pathway for urea transport across this epithelium [41 && ].
Bladder
The ]. A genome-wide association study found a link between a polymorphism in UT-B and bladder cancer in a Northern India population [43] . An editorial suggested that the demonstration of UT-B protein in human bladder may explain the observation of a link between UT-B1 and bladder cancer [44] . High protein diets can lead to high urinary urea concentrations, which may be carcinogenic in rat bladder [45] . UT-B expression in the urothelium of the American black bear, an animal that hibernates, was similar to that found in other mammals [46] .
Gastrointestinal tract/rumen
UT-B is important for salvaging urea nitrogen in the bovine gastrointestinal tract, especially in the rumen [47] . The serosal-to-mucosal flux of urea across the isolated ruminal epithelium is mediated by UT-B, as well as aquaporins 3, 7, and 10, in Holstein calves [48] . UT-B and aquaporin-3 protein abundances, but not aquaporin-7, were increased in calves during the transition from milk-feeding to solid-feeding [49] . Sheep rumen expresses both UT-B1 and UT-B2 transcripts by PCR, and urea transport was regulated by changes in pH and ammonia concentrations [50] . In primary cultures of goat rumen epithelial cells, short-chain fatty acids and acid pH increased UT-B mRNA and protein abundance [51] . Ruminal UT-B protein was also increased when the goats were fed a diet with large amounts of nitrogen and nonfiber carbohydrates [51] .
Other recent findings
A high salt diet (8% for 2 weeks) reduced UT-B mRNA and protein abundances in the choroid plexus of Dahl S, but not Dahl R, rats [52 & ]. UT-A mRNA abundance was not altered by the high salt diet in either Dahl S or Dahl R rats [52 & ]. UT-B knockout mice have an atrial-ventricular conduction block [53] . A proteomics study found that 15 proteins involved in mitochondrial complexes I, III, IV, and V of the respiratory chain were downregulated [54] . These changes could reduce electron transport chain activity, lead to mitochondrial dysfunction, and explain the atrial-ventricular conduction block [54] .
Mice were implanted with either UT-B expressing cells or control cells to investigate the utility of a gene reporter system based upon UT-B and C-13 hyperpolarized urea [55] . UT-B lowered the apparent diffusion coefficient of hyperpolarized urea, suggesting that it has the potential to be used in vivo as a magnetic resonance-based gene reporter [55] .
UREARETICS
Urea transporter inhibitors are attractive targets for the development of novel diuretics (reviewed in [56, 57] ). As conventional diuretics target sodium transporters, agents inhibiting urea transporters could provide synergistic effects. Those that target UT-A1 are particularly attractive as UT-A1 is located in the last portion of the IMCD and thus may have less risk for side-effects, such as hypokalemia, than conventional diuretics (Fig. 4) .
A high-throughput assay was used to identify UT-A inhibitors [58] . Compounds were identified using a structure-activity analysis that selectively inhibited UT-A by a noncompetitive mechanism with an IC 50 of 1 mmol [58] . Administering an indole thiazole or g-sultambenzosulfonamide intravenously to rats resulted in diuresis with more urea than salt excretion, even when the rats were given dDAVP [58] . Thus, these UT-A inhibitors may be clinically useful in patients with volume overload and high vasopressin levels, such as congestive heart failure or cirrhosis [58] .
A thienoquinolin, PU-14, inhibits both UT-A and UT-B urea transporters and causes a diuresis [59] . By inhibiting UT-B, PU-14 may be a novel therapy for hypertension [40 && ]. Structure-activity analysis was used to identify a thienoquinolin, PU-48, that was a more potent inhibitor of UT-A in the IMCD [60 & ]. PU-48 caused diuresis in both wild-type and UT-B knockout mice, indicating that its effect was to inhibit UT-A. PU-48 inhibited urea permeability in perfused rat IMCDs [60 & ]. The diuresis induced by PU-48 did not change serum sodium, chloride, or potassium levels, suggesting that a UT-A inhibitor acting on the IMCD would have fewer side-effects on electrolyte homeostasis than conventional diuretics [60 & ]. Primary high-throughput virtual screening was used to identify four classes of compounds with UT-B inhibitory activity and to predict a human UT-B model [61] . Comparing UT-B from different species allowed a novel inhibitory mechanism for UT-B to be postulated and suggested that phenylalanine198 in mouse and rat UT-B might impede inhibitor-UT-B interactions [55] .
A cell-based high-throughput assay identified 2,7-distributed fluorenones as urea transporter inhibitors [62] . The most potent compounds inhibited UT-A1 and UT-B with an IC 50 of 1 mmol [62] . Computational docking to a UT-A1 homology model suggested that the inhibitor binds to the urea transporter cytoplasmic domain at a site away from the putative urea-binding site [62] .
Urea analogs, such as dimethylthiourea (DMTU), inhibit UT-A1, and UT-B [63 & ,64 && ]. Chronic treatment of rats with DMTU resulted in a sustained and reversible reduction in urine osmolality, a three-fold increase in urine volume, and Urea transporters and urearetics Klein and Sands mild hypokalemia [64 && ]. Rats treated with DMTU had a greater diuresis and reduced urinary salt loss than rats treated with furosemide [64 && ]. DMTU treatment also prevented hyponatremia and water retention in a rat model of the syndrome of inappropriate antidiuretic hormone secretion [64 && ]. To identify more potent and selective inhibitors than DMTU, 36 thiourea analogs were tested [63 & ]. The most potent compound, 3-nitrophenyl-thiourea, inhibited both UT-A1 and UT-B with an IC 50 of 0.2 mmol. Other analogs were found that were relatively selective for UT-A1 or UT-B [63 & ]. A computational and molecular dynamic simulation approach was used to investigate the structural characteristics of Desulfovibrio vulgaris urea transporter (dvUT), a bacterial urea transporter [65] . Three urea-binding sites were identified. The simulations also suggested that dvUT is water permeable. DvUT was used as a model protein, along with the Larginine/agmatin antiporter and lactose permease from Escherichia coli, in a study to determine detergent-binding capacity and phospholipid content of membrane proteins with the ultimate goal of successfully crystallizing membrane proteins [66] .
CONCLUSION
Additional research into the regulation of urea transporters, especially UT-A1, will be important for the development of urearetic agents. If these agents can be developed for clinical use, they would add a novel class of diuretic that may have fewer side-effects on serum electrolytes than conventional diuretics. Urearetics work by increasing luminal urea concentration and causing an osmotic diuresis, so one might expect them to cause hypernatremia. However, the studies reviewed herein have not reported hypernatremia. Urea transport inhibitors may be especially useful in conditions associated with reduced circulating volume and hyponatremia, such as congestive heart failure or cirrhosis.
Elucidating nonvasopressin-mediated pathways to stimulate UT-A1 function may be important for the treatment of patients with nephrogenic diabetes insipidus. Activating alternate pathways to increase UT-A1 function could reduce the severity of the urine-concentrating defects. The study reports on a novel mechanism by which PKC regulates UT-A3 function by increasing glycan sialyation through ST6 beta-galactosamide alpha-2,6-sialyltranferase 1. 
